Abstract
Interstitial lung disease (ILD) is a major cause of death and disability in patients with polymyositis or dermatomyositis. To begin to improve patient outcomes, the clinical, demographic and therapeutic factors associated with poor prognosis for patients with ILD associated with polymyositis or dermatomyositis need to be identified.
Original language | English (US) |
---|---|
Pages (from-to) | 253-254 |
Number of pages | 2 |
Journal | Nature Reviews Rheumatology |
Volume | 14 |
Issue number | 5 |
DOIs | |
State | Published - May 1 2018 |
ASJC Scopus subject areas
- Rheumatology